NCT01632917View on ClinicalTrials.gov

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Healthy
Interventions
DRUG

ATX-101 - U.S.

US ATX-101, 10 mg/mL, one dosing session in the submental area

DRUG

ATX-101 - EU

EU ATX-101, 10 mg/mL, one dosing session in the submental area

Trial Locations (1)

33027

Comprehensive Clinical Development, Miramar

Sponsors
All Listed Sponsors
lead

Kythera Biopharmaceuticals

INDUSTRY

NCT01632917 - Open-Label Pharmacokinetic Study of Final Formulations of ATX-101 | Biotech Hunter | Biotech Hunter